| Type: |
Conjugated Primary Antibody |
| Conjugated with: |
594, ALEXA FLUOR® |
| Host organism: |
Rabbit (Oryctolagus cuniculus) |
| Target Protein/Peptide: |
CPLX2 |
| Specificity: |
This antibody reacts specifically with CPLX2 |
| Modification: |
No modification has been applied to this antibody |
| Modification site: |
None |
| Clonality: |
Polyclonal Antibody |
| Clone: |
Polyclonal Antibodies |
| Concentration: |
1ug per 1ul |
| Antigen Source: |
KLH conjugated synthetic peptide derived from human Complexin II |
| Applications: |
IF(IHC-P) |
| Applications with corresponding dilutions: |
IF(IHC-P)(1:50-200) |
| Cross reactive species: |
Mouse (Mus musculus), Rat (Rattus norvegicus), Human (Homo sapiens) |
| Cross Reactive Species details: |
However, note that due to limited knowledge it is impossible to predict with 100% guarantee that the antibody does not corss react with any other species, No significant cross reactivity has been observed for this antibody for the tested species |
| Background information: |
A progressive loss of Complexin 2 occurs in the brains of mice carrying the Huntington disease mutation, Changes in the neurotransmitter release might contribute to the motor, Complexin 1 and Complexin 2 are expressed in presynaptic terminals of inhibitory and excitatory hippocampal neurons, Complexin 2 may play a role in LTP (long term potentiation) following tetanic stimulation, Complexins are important regulators of transmitter release at a late step in calcium dependent neurotransmitter release or immediately after the calcium-triggering step of fast synchronous transmitter release and preceding vesicle fusion, Complexins promote SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptors) precomplex formation by binding to synaxin with its a-helical domain, Neurons lacking complexins show reduced transmitter release efficiency due to decreased calcium sensitivity of the synaptic secretion process, also designated Synaphin 1 and Synaphin 2, an autosomal dominant neurodegenerative disorder, and in cytoplasmic pools during early stages of development, contain an a-helical middle domain of approximately 58 amino acids, emotional and cognitive dysfunctions seen in these mice, respectively, Complexin 1 and Complexin 2 |
| Purification method: |
Purified by Protein A |
| Storage: |
50% glycerol and 0, Store at 4°, 09% sodium azide, C for 12 months, Water buffered solution containing 100ug/ml BSA |
| Excitation emission: |
590nm/617nm |
| Synonyms: |
CPX-2 DKFZp547D155 |
| Also known as: |
CPLX2 Polyclonal Antibody |
| Other name: |
Anti-CPLX2 Polyclonal |
| Advisory: |
For antibodies that are in liquid form or reconstituted lyophilized antibodies small amounts could become entrapped on the seal or the walls of the tube, Prior to use briefly centrifuge the vial to gather all the solution on the bottom, specificity and sensitivity, thus reducing its reactivity, Avoid freeze/thaw cycles as they may denaturate the polypeptide chains of the antibody |
| Properties: |
For facs or microscopy Alexa 1 conjugate |
| Conjugation: |
Alexa Fluor |
| Group: |
Polyclonals and antibodies |
| About: |
The advantage is that there are more epitopes available in a polyclonal antiserum to detect the proteins than in monoclonal sera, immunohistochemistry on frozen slices or parrafin fixed tissues, Polyclonals can be used for Western blot |
| Gene target: |
CPLX2 |
| Short name: |
Anti-CPLX2 (Polyclonal) Fluor 594 |
| Technique: |
Pabs are a collection of immunoglobulin , Polyclonal antibodies , each identifying a different , whereas , (pAbs) are mostly rabbit or goat , B cells, Polyclonal, antibodies , antigen, come from a single N cell lineage, epitope, molecules that react against a specific , monoclonal antibodies , that are secreted by different |
| Label: |
ALEXA |
| Alternative name: |
ALEXA Fluor 594, antibody to-complexin 2 (polyclonal) |
| Alternative technique: |
polyclonals |
| Alternative to gene target: |
921-L and CPX-2 and CPX2 and Hfb1, CPLX2 and IDBG-58509 and ENSG00000145920 and 10814, CPLX2 and IDBG-645067 and ENSBTAG00000013741 and 281711, Cplx2 and IDBG-153418 and ENSMUSG00000025867 and 12890, Cytoplasm, calcium-dependent protein binding, this GO :0000149 and SNARE binding and molecular function this GO :0005829 and cytosol and cellular component this GO :0006836 and neurotransmitter transport and biological process this GO :0006904 and vesicle docking involved in exocytosis and biological process this GO :0007399 and nervous system development and biological process this GO :0016079 and synaptic vesicle exocytosis and biological process this GO :0017075 and syntaxin-1 binding and molecular function this GO :0019905 and syntaxin binding and molecular function this GO :0030154 and cell differentiation and biological process this GO :0030425 and dendrite and cellular component this GO :0031201 and SNARE complex and cellular component this GO :0031915 and positive regulation of synaptic plasticity and biological process this GO :0042629 and mast cell granule and cellular component this GO :0043025 and neuronal cell body and cellular component this GO :0043303 and mast cell degranulation and biological process this GO :0045202 and synapse and cellular component this GO :0048306 and calcium-dependent protein binding and molecular function this GO :0070033 and synaptobrevin 2-SNAP-25-syntaxin-1a-complexin II complex and cellular component, this GO :0000149 : SNARE binding, this GO :0000149 : SNARE binding and also this GO :0017075 : syntaxin-1 binding and also this GO :0019905 : syntaxin binding and also this GO :0048306 : calcium-dependent protein binding, this GO :0017075 : syntaxin-1 binding, this GO :0019905 : syntaxin binding, this GO :0048306 : calcium-dependent protein binding, complexin 2 |
| Identity: |
2310 |
| Gene: |
CPLX2 |
More about : CPLX2 |
| Long gene name: |
complexin 2 |
| Locus: |
5q35, 2 |
| Discovery year: |
1999-09-09 |
| GenBank acession: |
U35100 |
| Entrez gene record: |
10814 |
| Pubmed identfication: |
7553862 16162394 |
| Havana BLAST/BLAT: |
OTTHUMG00000130665 |